|
|
Volumn 83, Issue 3, 2000, Pages 281-283
|
|
Changes in 18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
FLUORODEOXYGLUCOSE F 18;
DIAGNOSTIC AGENT;
GLUCOSE;
RADIOPHARMACEUTICAL AGENT;
CANCER SURVIVAL;
DIAGNOSTIC ACCURACY;
DIAGNOSTIC VALUE;
EDITORIAL;
EUROPE;
HUMAN;
PANCREAS CANCER;
PHARMACODYNAMICS;
POSITRON EMISSION TOMOGRAPHY;
PREDICTION;
PRIORITY JOURNAL;
QUANTITATIVE DIAGNOSIS;
COMPUTER ASSISTED EMISSION TOMOGRAPHY;
METABOLISM;
METHODOLOGY;
NEOPLASM;
NOTE;
PANCREAS TUMOR;
PRACTICE GUIDELINE;
PREDICTION AND FORECASTING;
SCINTISCANNING;
SENSITIVITY AND SPECIFICITY;
TISSUE DISTRIBUTION;
ANTINEOPLASTIC AGENTS;
EUROPE;
FLUORODEOXYGLUCOSE F18;
GLUCOSE;
HUMANS;
NEOPLASMS;
PANCREATIC NEOPLASMS;
PRACTICE GUIDELINES;
PREDICTIVE VALUE OF TESTS;
RADIOPHARMACEUTICALS;
SENSITIVITY AND SPECIFICITY;
TISSUE DISTRIBUTION;
TOMOGRAPHY, EMISSION-COMPUTED;
|
|
EID: 0033623988
PISSN: 00070920
EISSN: None
Source Type: Journal
DOI: 10.1054/bjoc.2000.1342 Document Type: Editorial |
|
Times cited : (15)
|
|
References (13)
|
